98 related articles for article (PubMed ID: 26248194)
1. Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas.
Takatani H; Oka M; Fukuda M; Narasaki F; Nakano R; Ikeda K; Terashi K; Kinoshita A; Soda H; Kanda T; Schneider E; Kohno S
Jpn J Cancer Res; 1997 Feb; 88(2):160-5. PubMed ID: 9119744
[TBL] [Abstract][Full Text] [Related]
2. Decoding Serine Metabolism: Unveiling Novel Pathways for Evolving Cancer Therapies.
Lau A; Blenis J; Burgos-Barragan G
Cancer Res; 2024 Apr; 84(8):1191-1194. PubMed ID: 38364233
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.
Koerber RM; Held SAE; Heine A; Kotthoff P; Daecke SN; Bringmann A; Brossart P
Exp Hematol Oncol; 2015; 4():21. PubMed ID: 26251761
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ; Heffner LT; Langston AA; Lechowicz MJ; Lonial S; Flowers CR
Br J Haematol; 2015 Nov; 171(4):539-46. PubMed ID: 26248505
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Thomas A; Redon CE; Sciuto L; Padiernos E; Ji J; Lee MJ; Yuno A; Lee S; Zhang Y; Tran L; Yutzy W; Rajan A; Guha U; Chen H; Hassan R; Alewine CC; Szabo E; Bates SE; Kinders RJ; Steinberg SM; Doroshow JH; Aladjem MI; Trepel JB; Pommier Y
J Clin Oncol; 2018 Jun; 36(16):1594-1602. PubMed ID: 29252124
[TBL] [Abstract][Full Text] [Related]
6. Emerging Role of Plant-Based Dietary Components in Post-Translational Modifications Associated with Colorectal Cancer.
Rodríguez-García C; Gutiérrez-Santiago F
Life (Basel); 2023 Jan; 13(2):. PubMed ID: 36836621
[TBL] [Abstract][Full Text] [Related]
7. Different Camptothecin Sensitivities in Subpopulations of Colon Cancer Cells Correlate with Expression of Different Phospho-Isoforms of Topoisomerase I with Different Activities.
Tesauro C; Keller JG; Gromova I; Gromov P; Frohlich R; Erlandsen JU; Andersen AH; Stougaard M; Knudsen BR
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32423158
[TBL] [Abstract][Full Text] [Related]
8. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Shaojun C; Li H; Haixin H; Guisheng L
Cancer Biol Ther; 2018 Mar; 19(3):153-159. PubMed ID: 29261002
[TBL] [Abstract][Full Text] [Related]
9. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract][Full Text] [Related]
10. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Fukuoka K; Adachi J; Nishio K; Arioka H; Kurokawa H; Fukumoto H; Ishida T; Nomoto T; Yokote H; Tomonari A; Narita N; Yokota J; Saijo N
Jpn J Cancer Res; 1997 Oct; 88(10):1009-16. PubMed ID: 9414664
[TBL] [Abstract][Full Text] [Related]
11. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Zhao M; Gjerset RA
PLoS One; 2015; 10(8):e0134929. PubMed ID: 26248194
[TBL] [Abstract][Full Text] [Related]
13. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2012; 7(11):e50427. PubMed ID: 23185622
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
